Editor's Note: Green and red arrows refer to intraday stock price movement.
NEW YORK (
STOCK COMMENTS / EPS CHANGES
estimates were raised through 2012 and its price target was increased to $375 at ThinkEquity. Company is seeing better demand and improving its distribution. Buy rating.
price target cut to $54 at Goldman Sachs. Company could see lower Humira sales. Neutral rating.
price target upped to $24 at Oppenheimer. Recent meeting with management suggests that the company can return to more steady profitability, Oppenheimer said.
price target lowered to $78 at RBC Capital. Changing the design of the 787 power system will lead to further delays, RBC said. Outperform rating.
estimates, target increased at Citigroup. Estimates were raised through 2012. Company should continue to generate solid free cash flow, Citigroup said. Buy rating and new $87 price target.
estimates were raised through 2011 at Argus Research. Company continues to improve profitability, Argus said. Buy rating and new $10 price target.
price target boosted to $26 at Deutsche Bank. Estimates also increased, given higher expected MPU sales. Buy rating.
price target was boosted to $72 from $66 at Bank of America/Merrill Lynch on increased comfort with underlying North American beverage pricing trends. Maintain Buy rating.
price target was increased to $60 from $55 at Bank of America/Merrill Lynch. November comps set to rebound after weak October, Bank of America/Merrill Lynch said. Maintain Buy rating.
numbers boosted at Citigroup. Shares now seen reaching $46, and estimates were raised, given higher realized core growth. Buy rating.
numbers reduced at Wunderlich Securities. Shares now seen reaching $24. Estimates were also cut, as the proposed purchase of
fell through, Wunderlich said. Buy rating.
estimates, target lowered at Citigroup. Shares now seen reaching $28. Estimates also reduced, given lower hedge prices and new equity issuance. Hold rating.
Robbins & Meyers
numbers raised at Keybanc. Shares now seen reaching $36. Estimates also increased, as base business trends appear solid. Buy rating.
estimates, target cut at Needham.Shares now seen reaching $57. Estimates also reduced to reflect the stronger dollar. Buy rating.
estimates, target raised at Goldman Sachs.Shares now seen reaching $22. Company is growing faster than its peers and should realize higher merger synergies. Neutral rating.
( SOLR) numbers lowered at UBS. Shares now seen reaching $9.50. Estimates also reduced, as the company could see higher competition for solar furnaces. Buy rating.
price target boosted to $58 from $54 at Credit Suisse. Slowing momentum, but still expect 12% EBIT growth in 2011, Credit Suisse said. Maintain Outperform rating.
This article was written by a staff member of TheStreet.